ZhongSheng Pharmaceutical announced on September 29 that the company has obtained the Drug Registration Certificate for Emedastine Difumarate Eye Drops issued by the National Medical Products Administration. The drug is an ophthalmic preparation with a specification of 0.05% (5 ml: 2.5 mg), classified as a Category 4 chemical drug. According to the Menet database, total sales of Emedastine Difumarate Eye Drops from 2023 to 2025 were 88.08 million yuan, 81.55 million yuan, and 97.73 million yuan respectively. In the first half of 2026, ZhongSheng Pharmaceutical achieved revenue of 1 billion yuan and net profit attributable to the parent company of 111 million yuan.
Guangdong Zhongsheng Pharmaceutical Co LtdObtained Drug Registration Certificate from the National Medical Products Administration for Emedastine Difumarate Eye Drops, enabling the product to be marketed.
